RecruitingNot ApplicableNCT07044557
MeDex: No Perioperative Dexamethasone in Brain Metastases
Sponsor
University of Louisville
Enrollment
35 participants
Start Date
May 1, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
Perioperative treatment of newly diagnosed cancer patients with brain metastasis without dexamethasone (Dex).
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This study is testing whether brain tumor surgery can be done safely without using steroid medication (dexamethasone) before and after the operation. Doctors routinely give steroids to reduce brain swelling, but steroids have side effects — this trial wants to find out if skipping them is just as safe.
**You may be eligible if...**
- You are 18 or older
- You have a brain tumor on imaging that is suspected or confirmed to be a metastasis (cancer that spread from elsewhere in the body)
- You are able to move around on your own more than half the day
- Your brain scan shows minimal shifting of brain structures (midline shift ≤10 mm)
- Surgery is planned to remove most of the tumor
- You have not used steroids recently
**You may NOT be eligible if...**
- You have additional untreatable brain metastases larger than 2 cm
- You have small cell lung cancer
- You have been on steroids or need them for another condition
- You have severe kidney disease
- You are pregnant or breastfeeding
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERWithholding perioperative Dexamethasone
Patients will not receive perioperative Dex before, during, and up to 3 weeks after surgery.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07044557
Related Trials
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
NCT0355039186 locations
Stereotactic Radiosurgery Dose Escalation for Brain Metastases
NCT023905181 location
ioMRI in the Surgery of Brain Metastases.
NCT071976321 location
Development of MRF for Characterization of Brain Tumors After Radiotherapy
NCT061010692 locations
Neoadjuvant vs. Intraoperative vs. Adjuvant Resection Cavity Radiotherapy of Brain Metastases
NCT058713071 location